Femta Pharmaceuticals Announces IND Filing of FM101, a Novel Monoclonal Antibody Targeting IL-6 with Potent Anti-Inflammatory Activity  
8/1/2011 8:06:33 AM

SAN DIEGO--(BUSINESS WIRE)--Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).